| Autor: |
Broadwell, Aaron, Schechtman, Joy, Conaway, Douglas, Kivitz, Alan, Shiff, Natalie J., Black, Shawn, Xu, Stephen, Langholff, Wayne, Schwartzman, Sergio, Curtis, Jeffrey R. |
| Rok vydání: |
2023 |
| DOI: |
10.6084/m9.figshare.22624733 |
| Popis: |
Additional file 1. Figure S1. Mean changes from baseline at Month 6 and Month 12 in CDAI score biologic-naïve and biologic-experienced patients receiving IV golimumab with and without methotrexate (observed data). Figure S2. Proportions of biologic-naïve patients in remission (CDAI ≤ 2.8) and with low disease activity (CDAI > 2.8 to ≤ 10), moderate disease activity (CDAI > 10 to ≤22), and high disease activity (CDAI > 22) at baseline and Months 3, 6, and 12 by treatment group (IV golimumab+methotrexate and IV golimumab without methotrexate). Figure S3. Proportions of biologic-experienced patients in remission (CDAI ≤ 2.8) and with low disease activity (CDAI > 2.8 to ≤ 10), moderate disease activity (CDAI > 10 to ≤ 22), and high disease activity (CDAI > 22) at baseline and Months 3, 6, and 12 by treatment group (IV golimumab+methotrexate and IV golimumab without methotrexate). |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
